The estimated Net Worth of Carl Goldfischer is at least $33.7 million dollars as of 11 November 2020. Carl Goldfischer owns over 5,000 units of Epizyme Inc stock worth over $7,350 and over the last 11 years he sold EPZM stock worth over $33,428,558. In addition, he makes $231,162 as Independent Director at Epizyme Inc.
Carl has made over 12 trades of the Epizyme Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of EPZM stock worth $60,350 on 11 November 2020.
The largest trade he's ever made was buying 555,555 units of Epizyme Inc stock on 12 January 2016 worth over $4,999,995. On average, Carl trades about 47,708 units every 70 days since 2013. As of 11 November 2020 he still owns at least 5,000 units of Epizyme Inc stock.
You can see the complete history of Carl Goldfischer stock trades at the bottom of the page.
Dr. Carl M. Goldfischer M.D. serves as Independent Director of the Company. Dr. Goldfischer has served as an Investment Partner, Managing Director, member of the board of directors and member of the executive committee of Bay City Capital LLC, or Bay City Capital, a life sciences investment firm and a holder of more than 5% of our voting securities, since January 2000. Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer of ImClone Systems Incorporated, a biopharmaceutical company. Since 2004, Dr. Goldfischer has served on the board of directors of EnteroMedics Inc., a publicly traded medical device company. Dr. Goldfischer received a B.A. from Sarah Lawrence College and an M.D. with honors in Scientific Research from Albert Einstein College of Medicine
As the Independent Director of Epizyme Inc, the total compensation of Carl Goldfischer at Epizyme Inc is $231,162. There are 11 executives at Epizyme Inc getting paid more, with Robert Bazemore having the highest compensation of $4,173,620.
Carl Goldfischer is 61, he's been the Independent Director of Epizyme Inc since 2009. There are 4 older and 14 younger executives at Epizyme Inc. The oldest executive at Epizyme Inc is Kenneth Bate, 69, who is the Independent Director.
Carl's mailing address filed with the SEC is OLE MAALOES VEJ 3, C/O GALECTO, INC., COPENHAGEN N G7, G7, DK-2200.
Over the last 11 years, insiders at Epizyme Inc have traded over $122,255,844 worth of Epizyme Inc stock and bought 45,285,781 units worth $322,885,823 . The most active insiders traders include Forest Baskett, Scott D Sandell et Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of $394,367. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth $1,704,500.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Epizyme Inc executives and other stock owners filed with the SEC include: